Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing

Virtually every cellular process is affected by diet and this represents the foundation of dietary management to a variety of small animal disorders. Special attention is currently being paid to a family of naturally occurring lipid amides acting through the so-called autacoid local injury antagonis...

Full description

Bibliographic Details
Published in:	Veterinary Sciences
Main Authors:	Enrico Gugliandolo, Alessio Filippo Peritore, Cristian Piras, Salvatore Cuzzocrea, Rosalia Crupi
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Subjects:	palmitoylethanolamide PEA ALIAmides autacoid local injury antagonism endocannabinoid wellbeing
Online Access:	https://www.mdpi.com/2306-7381/7/2/78

Similar Items

Oral Supplementation with Ultramicronized Palmitoylethanolamide for Joint Disease and Lameness Management in Four Jumping Horses: A Case Report
by: Enrico Gugliandolo, et al.
Published: (2020-08-01)

Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art
by: Giorgia della Rocca, et al.
Published: (2022-08-01)

Oral Adelmidrol Administration Up-Regulates Palmitoylethanolamide Production in Mice Colon and Duodenum through a PPAR-γ Independent Action
by: Alessandro Del Re, et al.
Published: (2022-05-01)

Therapeutic Use of Palmitoylethanolamide as an Anti-Inflammatory and Immunomodulator
by: Maria Clara Inácio de Sá, et al.
Published: (2023-12-01)

Co-micronized palmitoylethanolamide/polydatin treatment causes endometriotic lesion regression in a rodent model of surgically-induced endometriosis
by: Rosanna Di Paola, et al.
Published: (2016-10-01)

Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans
by: Eugenia Landolfo, et al.
Published: (2022-05-01)

Palmitoylethanolamide/Baicalein Regulates the Androgen Receptor Signaling and NF-κB/Nrf2 Pathways in Benign Prostatic Hyperplasia
by: Ramona D’Amico, et al.
Published: (2021-06-01)

Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation
by: Valeria Di Stefano, et al.
Published: (2025-05-01)

Corrigendum: Oral ultramicronized palmitoylethanolamide: plasma and tissue levels and spinal antihyperalgesic effect
by: Stefania Petrosino, et al.
Published: (2024-06-01)

Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?
by: Giorgia della Rocca, et al.
Published: (2021-03-01)

An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events
by: Marika Cordaro, et al.
Published: (2020-03-01)

A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models
by: Domenico Britti, et al.
Published: (2017-08-01)

Management of Traumatic Brain Injury: From Present to Future
by: Rosalia Crupi, et al.
Published: (2020-04-01)

A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review
by: Giustino Varrassi, et al.
Published: (2024-12-01)

Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies
by: Anna Paola Capra, et al.
Published: (2023-08-01)

Co-ultramicronized palmitoylethanolamide/luteolin promotes neuronal regeneration after spinal cord injury
by: Rosalia eCrupi, et al.
Published: (2016-03-01)

Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
by: Damiana Scuteri, et al.
Published: (2022-08-01)

Focus on the Endogenous Cannabinoid System in Migraine
by: Domenico Chirchiglia, et al.
Published: (2017-08-01)

Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma
by: Paterniti Irene, et al.
Published: (2013-02-01)

N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion
by: Daniela Impellizzeri, et al.
Published: (2019-05-01)

Corrigendum: Palmitoylethanolamide attenuates neurodevelopmental delay and early hippocampal damage following perinatal asphyxia in rats
by: Maria I. Herrera, et al.
Published: (2022-12-01)

Effects of autacoid inhibitors and of an antagonist on malaria infection in mice
by: E.O. Iwalewa, et al.
Published: (2004-08-01)

To Go Where Nature Leads: Focus on Palmitoylethanolamide and Related ALIAmides as Innovative Approach to Neuroinflammatory and Pain-Related Disease States in Honor of Doctor Francesco Della Valle
by: Salvatore Cuzzocrea, et al.
Published: (2023-10-01)

Prostanoids in health and disease
by: Emer M. Smyth, et al.
Published: (2009-01-01)

PEA/Polydatin: Anti-Inflammatory and Antioxidant Approach to Counteract DNBS-Induced Colitis
by: Alessio Filippo Peritore, et al.
Published: (2021-03-01)

Aliamidi e duloxetina nel trattamento del low back pain - Aliamides and duloxetina in the treatment of low back pain
by: Paolo Desio
Published: (2016-01-01)

Administration of palmitoylethanolamide in combination with topiramate in the preventive treatment of nummular headache
by: Chirchiglia D, et al.
Published: (2016-07-01)

Therapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders
by: Marija Branković, et al.
Published: (2024-05-01)

Short-term efficacy of a fixed association of Palmitoylethanolamide and other phytochemicals as add-on therapy in the management of chronic pain in elderly patients: a real-world retrospective study
by: Walter Gianni, et al.
Published: (2018-05-01)

Effects of the glial modulator palmitoylethanolamide on chronic pain intensity and brain function
by: Alshelh Z, et al.
Published: (2019-08-01)

Partial Reversal of Striatal Damage by Palmitoylethanolamide Administration Following Perinatal Asphyxia
by: Lucas D. Udovin, et al.
Published: (2020-01-01)

Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications
by: Marta Valenza, et al.
Published: (2022-08-01)

Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome
by: Chirchiglia D, et al.
Published: (2019-02-01)

Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study
by: Jordi Faig-Martí, et al.
Published: (2017-03-01)

Antioxidant and Anti-Inflammatory Activity of Combined Phycocyanin and Palmitoylethanolamide in Human Lung and Prostate Epithelial Cells
by: Loredana Bergandi, et al.
Published: (2022-01-01)

Fixed combination of palmitoylethanolamide and melatonin in preventive therapy of migraine: results from a randomized clinical trial
by: Vincenzo Piccolo, et al.
Published: (2025-04-01)

Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells
by: Chiara Camoglio, et al.
Published: (2024-04-01)

A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol
by: Zoya Huschtscha, et al.
Published: (2023-03-01)

Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery
by: Carmelo Puglia, et al.
Published: (2018-03-01)

Inflammatory-Targeted Lipid Carrier as a New Nanomaterial to Formulate an Inhaled Drug Delivery System
by: Eleonora Maretti, et al.
Published: (2024-04-01)